Consequently, FRP5-based CARs are less likely than trastuzumab-based CARs to get activated by ErbB2 expressed at moderate levels, which is supported by data from a clinical trial in sarcoma patients with ErbB2-specific T cells carrying an FRP5-based second-generation CAR, where no on-target/off-tumor toxicities were observed (141). The gene discussed is ERBB2; the disease is neoplasm.